Revolve Wealth Partners LLC Takes $202,000 Position in Humana Inc. (NYSE:HUM)

Revolve Wealth Partners LLC bought a new position in shares of Humana Inc. (NYSE:HUM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 798 shares of the insurance provider’s stock, valued at approximately $202,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Creative Financial Designs Inc. ADV boosted its holdings in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares during the last quarter. Atwood & Palmer Inc. acquired a new stake in Humana in the 3rd quarter worth about $29,000. Ashton Thomas Securities LLC purchased a new stake in Humana in the 3rd quarter valued at about $31,000. Your Advocates Ltd. LLP grew its holdings in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the period. Finally, LRI Investments LLC increased its holdings in shares of Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after buying an additional 143 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of Humana stock opened at $303.57 on Wednesday. The firm has a market cap of $36.55 billion, a PE ratio of 26.89, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The firm’s 50-day simple moving average is $274.93 and its 200-day simple moving average is $303.69. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities analysts forecast that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.32% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on HUM. Morgan Stanley increased their target price on shares of Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Jefferies Financial Group lowered shares of Humana from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $519.00 to $253.00 in a research report on Monday, October 7th. Oppenheimer reduced their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a report on Thursday, October 3rd. Leerink Partnrs downgraded Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Truist Financial boosted their price objective on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $297.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.